These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 32430651)

  • 1. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
    Albini A; Di Guardo G; Noonan DM; Lombardo M
    Intern Emerg Med; 2020 Aug; 15(5):759-766. PubMed ID: 32430651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
    Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
    G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
    Rossi GP; Sanga V; Barton M
    Elife; 2020 Apr; 9():. PubMed ID: 32250244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
    Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
    Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
    Patoulias D; Katsimardou A; Stavropoulos K; Imprialos K; Kalogirou MS; Doumas M
    Curr Hypertens Rep; 2020 Sep; 22(11):90. PubMed ID: 32910274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety.
    Akhtar S; Benter IF; Danjuma MI; Doi SAR; Hasan SS; Habib AM
    J Drug Target; 2020; 28(7-8):683-699. PubMed ID: 32700580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
    Sadria M; Layton AT
    PLoS Comput Biol; 2020 Oct; 16(10):e1008235. PubMed ID: 33031368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.
    Wang JJ; Edin ML; Zeldin DC; Li C; Wang DW; Chen C
    Pharmacol Ther; 2020 Nov; 215():107628. PubMed ID: 32653530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.
    Guzik TJ; Mohiddin SA; Dimarco A; Patel V; Savvatis K; Marelli-Berg FM; Madhur MS; Tomaszewski M; Maffia P; D'Acquisto F; Nicklin SA; Marian AJ; Nosalski R; Murray EC; Guzik B; Berry C; Touyz RM; Kreutz R; Wang DW; Bhella D; Sagliocco O; Crea F; Thomson EC; McInnes IB
    Cardiovasc Res; 2020 Aug; 116(10):1666-1687. PubMed ID: 32352535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications.
    Barillà F; Bassareo PP; Calcaterra G; Romeo F; Mehta JL
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):630-633. PubMed ID: 32740495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
    Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
    Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
    Danser AHJ; Epstein M; Batlle D
    Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.
    Bravi F; Flacco ME; Carradori T; Volta CA; Cosenza G; De Togni A; Acuti Martellucci C; Parruti G; Mantovani L; Manzoli L
    PLoS One; 2020; 15(6):e0235248. PubMed ID: 32579597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?
    Shyh GI; Nawarskas JJ; Cheng-Lai A
    Cardiol Rev; 2020; 28(4):213-216. PubMed ID: 32496364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
    Vázquez-Cornejo E
    Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
    Cheng H; Wang Y; Wang GQ
    J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
    Mancia G; Rea F; Ludergnani M; Apolone G; Corrao G
    N Engl J Med; 2020 Jun; 382(25):2431-2440. PubMed ID: 32356627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
    Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG
    EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
    Kurdi A; Abutheraa N; Akil L; Godman B
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
    Sommerstein R; Kochen MM; Messerli FH; Gräni C
    J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.